

Co-regulation of miRNA biogenesis and alternative pre-mRNA splicing of host gene

Ashley A. Reich

Department of Biology
Lake Forest College
Lake Forest, Illinois 60045

Abstract

This study focuses on two post-transcriptional gene expression regulatory mechanisms found ubiquitously in the body and widely expressed in neuronal tissue: host gene pre-messenger RNA (pre-mRNA) alternative splicing and microRNA (miRNA) biogenesis. Most of the past research has primarily looked at how miRNAs regulate gene expression at the pre-mRNA level, and little has been done on how these two processes coexist. We hypothesized that the two processes are co-regulated when the miRNA is located within the intron of a pre-mRNA, and that miRNA biogenesis impacts the inclusion of alternative exons in the final mRNA transcript. Our results revealed that manipulations to both processes had effects on the other process. We conclude that some level of co-regulation exists between these two processes, and that the Microprocessor may have some role in alternative splicing.

Introduction

Diversity of gene expression regulation

Each cell produces many different proteins in order to differentiate itself from other cells and to function properly. This phenomenon is the same for unicellular bacteria as well as for each of the trillions of cells found in the human body. Unlike prokaryotic cells, which have quick cell division to maintain homeostasis, eukaryotic cells rely on gene expression regulation to either increase quantities of one particular protein or a variation of proteins. It was previously thought that humans have hundreds of thousands of genes that express all of the proteins in our bodies. As it turns out, only 20,000 to 25,000 genes are coded in the genome (Human Genome Project). How is it that only 20,000 genes can make up all of the proteins that we need for an entire body's survival? This is where the mechanisms of gene expression regulation give cells and organisms their diversity.

According to the central dogma of cell biology, while in the nucleus, the double-stranded DNA is first transcribed into RNA. This newly made strand of RNA then undergoes translation where it is made into a protein. At both of these steps there is an opportunity for gene expression regulation to occur to continue diversifying the composition of the cell. Gene expression regulation occurs even in the earliest stages of DNA replication (Figure 1). Cells have the capability of changing their chromatin structure using a remodeling complex, which condenses and decondenses itself. Decondensing allows for areas of DNA to be transcribed by polymerase (Alberts et al., p. 279). Another method of gene expression regulation at the structural level occurs through chemical modifications to the chromatin. Methylation and phosphorylation of the chromatin not only induce transient changes by attracting different proteins to those regions, but they also elicit permanent changes that then contribute to epigenetic inheritance that passes along these modifications (Alberts et al., p. 192).

Transcriptional control is the next process wherein

*This author wrote the paper as a part of a senior thesis under the direction of Dr. Tsend Rosalind Franklin University of Medicine and Science

gene expression regulation can occur. Transcriptional regulators can come in various forms, but all function to alter the rate of transcription from DNA to RNA by switching genes on or off (Alberts et al., p. 278). Once the precursor-messenger RNA (pre-mRNA) has been successfully transcribed, it is processed into mature mRNA where it can be even further regulated throughout RNA processing and throughout translation into protein.

There are many different ways for genes to be regulated during the processing of pre-mRNA to mRNA. Most mRNAs are capped at their 5' end in order to stabilize the transcript and to guide the mRNA to the ribosome to begin translation (Gerstel et al., 1992; Alberts et al., p. 290). Another means of post-transcriptional regulation that gives stability to mRNAs and assists in translation is the process of polyadenylation, which is the addition of the nucleotide adenosine to the 3' end of the mRNA (Alberts et al., p. 241). Two other post-transcriptional processes that regulate gene expression are alternative pre-mRNA splicing and RNA interference through microRNAs (miRNAs), which are the focus of this study.




Figure 1. The six steps of gene regulation shown in this figure are just a few examples of the many different ways genes can be regulated. While still in the nucleus, genes undergo regulation before and after transcription occurs. In genomic regulation, as seen in step 1, chromatin can condense or decondense to allow different genes to be transcribed. More regulation occurs through DNA modifications as seen in step 2. At this step, acetylation and methylation of the DNA can cause temporary or more permanent changes in gene expression. Once the strands of DNA have been transcribed by RNA polymerase II into pre-mRNA, capping of the 5' end and alternative splicing of the pre-mRNA transcripts can occur as seen in step 3 of the post-transcriptional modifications. Boxes represent exons and lines represent introns that are spliced out via the spliceosome.

Also occurring in step 3, is polyadenylation of the mRNA transcript to further ensure stability. The polyadenylated strand of mRNA is then transported out of the nucleus where it is translated into a protein. Gene expression regulation can also occur prior to translation through the formations of stem-loops on the mRNA transcripts. These stem-loops can cause the mRNA to be even more stable once out of the nucleus, and thus constitutes step 5 in the regulation. Further regulation can be seen through post-translation modifications as seen at step 6. Adapted from Figure 8-3 in Alberts, B., Bray, D., Hopkin, K., Johnson, A., Lewis, J., Raff, M., . . . Walter, P. 2010. Essential cell biology. New York, NY: Garland Science, Taylor & Francis Group.

Alternative pre-mRNA splicing

The RNA transcript that is transcribed from a gene contains non-coding sequences (known as introns) and protein-coding sequences (known as exons). After transcription, the introns must be removed and the exons must be ligated together to produce the mRNA that codes for a specific protein; this process is called pre-mRNA splicing. Non-coding regions are spliced out of the transcript by a large macromolecular complex known as the spliceosome.

Alternative splicing is one process of gene expression regulation where multiple mRNA transcripts can be made from one single pre-mRNA, ultimately leading to different protein isoforms. The alternative splicing process is crucial for gene expression regulation and cellular diversity because over 95% of all mRNA transcripts are alternatively spliced (Figure 2A; Pan, Shai, Lee, Frey, & Blencowe, 2008; Wang, Z. et al., 2008).

A standard human gene is comprised of approximately eight exons that are on average a couple of hundred nucleotides in length. An intron is between 3,000 and 5,000 nucleotides, making up approximately 90% of the standard gene (Tazi, Bakkour, & Stamm, 2009). The non-coding regions of the genome, such as introns, were—until recently—considered 'junk' that did not contribute to cellular processes. However, it is now clear that many important regulatory sequences and non-coding functional RNAs are found in these non-coding regions.

Regulatory sequences play an important role in recruiting the spliceosome to introns and exons and signaling where splicing should occur. There are four basic types of RNA binding elements that can be found in both exons and introns of a pre-mRNA transcript: exonic splicing enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing enhancers (ISEs), and intronic splicing silencers (ISSs) (Figure 2B). Enhancers function by promoting the inclusion of the exon that they are either located in or neighbor and are further regulated by RNA binding proteins (Wang & Burge, 2008).

A class of RNA binding proteins called serine/arginine-rich proteins (SR proteins) generally act to promote splicing. Individual SR proteins recognize and bind to specific ESE sequences and recruit spliceosomal machinery such as small nuclear ribonucleoproteins (snRNPs) to a nearby splice site (Bush & Hertel, 2012). Silencers function by inhibiting the inclusion of exons through recognition by heterogeneous nuclear ribonucleoproteins (hnRNPs) (Wang & Burge, 2008; Bush & Hertel, 2012). Splicing regulatory elements (SREs) provide extremely useful information during the process of alternative splicing as to which exons should be included or skipped in the transcripts, and regulation of these SREs provide another layer of gene expression regulation by modulating alternative pre-mRNA splicing.

Alternative splicing can regulate the levels of mRNA expression in many different ways. For example, alternative splicing can alter the function of a protein by changing the

inclusion or skipping of functional or structural protein domains or by decreasing the stability of the mRNA transcripts (Stamm et al., 2005). These functions of alternative splicing can lead to a complete loss of function for some proteins, a gain of a new function, or give it an entirely new function in the cell (Stamm et al., 2005; Kelemen et al., 2012).

Alternative splicing function and dysfunction

Although alternative pre-mRNA splicing may lead to new functions for proteins, more often it is the cause of cellular dysfunction—ultimately leading to disease. Some gene mutations are capable of disrupting alternative splice sites, resulting in a shift of functional protein isoforms, while others can disrupt or inactivate the regulatory machinery of alternative splicing (Faustino & Cooper, 2003). This is seen in the inactivation of the Wilms' tumor suppressor gene (WT1) that is responsible for Frasier's syndrome. Frasier's syndrome is characterized by impairment of kidney and gonad development. This inactivation of WT1 is due to a deletion of three amino acids, which causes an increase in a zinc finger protein isoform with non-functioning properties (Klamt et al., 1998).

Alternative splicing has also been implicated in the dysregulation of transcription factors, transmembrane proteins, and alterations in cell signaling, all of which have been associated with cancer (Venables, 2004). In a familial study done by Hoffman et al. (1998), five out of the nine subjects had an intronic single nucleotide polymorphism of G to A, and all of their relatives had some form of cancer. This single nucleotide polymorphism causes an insertion of only eleven nucleotides into the mRNA transcript of the BRCA1 gene. This mutation ultimately leads to a truncated protein, which is translated from the mutation (Hoffman, Hallam, Venne, Lyon, & Ward, 1998). The previous examples of dysfunction help to show how complex and precise the mechanism must be in order to produce a normally functioning protein. Alternative splicing is a ubiquitous process, so any mutations that occur during the process of splicing can be disastrous to many different parts of the body. This is especially the case when dysfunction of alternative splicing arises in the nervous system, where it is most abundant (Licatalosi & Darnell, 2006).

Neuronal pre-mRNA splicing function and dysfunction

Alternative pre-mRNA splicing is highly abundant in the brain and plays an important role in neuronal development and regulation of mature neurons (Yeo, Holste, Kreiman, & Burge, 2004; Li, Lee, & Black, 2007). Alternative splicing is known to regulate processes such as neuronal migration, synaptogenesis, and postsynaptic responses (Ullrich, Ushkaryov, & Sudhof, 1995; Li et al., 2007; Norris & Calarco, 2012). During synaptogenesis, over one thousand transcripts for neuroligin have been found; demonstrating how prevalent alternative splicing is in neuronal tissue (Norris & Calarco, 2012). Spatio-temporal gene regulation has been shown to be very important in the development of the nervous system and throughout the body and helps to explain how tissues can express splicing patterning that is specific to that tissue and developmental stage (West & Greenberg, 2011). Although alternative splicing plays many important roles in the development of the nervous system, many neurological diseases have been associated with dysfunctions in alternative splicing. Spinal muscular atrophy (SMA) is characterized by the death of motor neurons exclusively in the anterior horns of the spinal cord. In 1995, Lefebvre et al. found that SMA is caused by a deletion in the survival of motor neuron 1 (SMN1) protein. Humans have a homologous gene, SMN2, which has a single nucleotide polymorphism of a C to a T, which disrupts the splicing

of the protein. The SMN protein is extremely important for many processes of the cell because SMN associates with a protein complex that assembles snRNPs that are essential for pre-mRNA splicing (Liu, Fischer, Wang, & Dreyfuss, 1997). SMA is just one example of how important proper alternative splicing is to the function of proteins and cellular processes. Understanding what causes the disarray that arises from mutation in alternative splicing will help in developing new therapies and strategies for correcting aberrant splicing.




Figure 2. Overview of alternative pre-mRNA splicing and regulating mechanisms. A) During pre-mRNA splicing the spliceosome selects some exons and skips others to produce different forms of the pre-mRNA transcript. The removal of some exons and not others allows the same genetic material to produce different proteins. Part A shows that two different protein isoforms can be produced by either including or skipping the blue exon in the mRNA transcript. B) There are many regulatory sequences within pre-mRNA transcripts that direct the spliceosome during splicing. The orange boxes represent splicing enhancers and the red boxes represent suppressors. Enhancers and suppressors are found in both exons and introns and together they promote the inclusion or skipping of neighboring exons. miRNAs, represented in green, can be found along the host transcript in exons, introns, and across the splice site. Is it possible for miRNAs to also regulate the splicing of their host gene?

MicroRNA processing

The second post-transcriptional process focused in this study is microRNA biogenesis. The first miRNA was reported in *Caenorhabditis elegans* in 1993 with the discovery of lin-4, though it was not until 2000 that the second miRNA, let-7, was found in other species including mammals (Lee, Feinbaum, & Ambros, 1993; Reinhart et al., 2000; Pasquinelli et al., 2000). In 2010, the registry database of all miRNAs (miRBase) reported that it contained over 17,000 distinct miRNA sequences from 170 different species (Kozomara & Griffiths-Jones, 2010). miRBase is an invaluable resource, providing an immense amount of information regarding where miRNAs are located and emphasizing their importance in the process of gene regulation

across species.

MiRNAs are initially transcribed from genes and fold into stem-loops, approximately 80 nucleotides in length, and additionally are processed into their mature transcript length of 20-25 nucleotides (Shomron & Levy, 2009). RNA polymerase II transcribes miRNA genes into primary transcripts (pri-miRNAs) that can then be excised by the Microprocessor complex into pre-miRNAs (Lee et al., 2004). The Microprocessor complex is composed of two primary proteins, DiGeorge syndrome critical region gene 8 (DGCR8; or Pasha in *Drosophila melanogaster* and *C. elegans*), and Drosha (Lee et al., 2003; Han et al., 2004; Han et al., 2006). After excision by the Microprocessor complex, the pre-miRNA transcript is cleaved into an approximately 70-nucleotide long pre-miRNA (Denli, Tops, Plasterk, Ketting, & Hannon, 2004). The pre-miRNAs are exported out of the nucleus by the nuclear export factor protein, exportin 5 (XPO5) where it is then processed into a miRNA duplex by the protein Dicer (Yi, Qin, Kreiman, & Burge, 2003; Bohnsack, Czaplinski, & Gorlich, 2004; Lund, Guttinger, Calado, Dahlberg, & Kutay, 2004; Bernstein, Caudy, Hammond, & Hannon, 2001). Dicer is also involved in processing the mature miRNA into the RNA-induced silencing complex (RISC) where it forms a complex with Argonaute (AGO) 1-4 and other RNA-binding proteins to carry out the mRNA silencing function (Ketting et al., 2001; Kim, 2005a).

MiRNAs can be located in various places in the genome: hosted exonically, intronically, and spanning a splice-site, but are primarily found in non-coding regions of the genome (intergenic regions) (Figure 3A; Kim, 2005b). Approximately 10% of the miRNAs found in coding regions of the genome are located within exons; the remaining 40% of miRNAs are located in introns. Some miRNAs comprise the entire length of small introns; these miRNAs are called mirtrons. Rather than undergoing cleavage by the Microprocessor, the mirtrons are spliced out by the spliceosome and then processed into mature miRNAs via the canonical pathway (Lai, 2003; Bartel, 2004).

Gene expression regulation, through miRNA processing, functions through a process called gene silencing. Regulation at the translational level occurs through three different processes: deadenylation of the 3' end of the mRNA transcript so that it becomes unstable, degrading the mRNA transcript so that it cannot be translated into a protein, or inhibiting ribosomal translation of the mRNA so that a protein is not translated (Figure 3A; Fazi & Nervi, 2008). All three miRNA silencing mechanisms are ubiquitously found, and ultimately affect the protein that is translated from the mRNA. MiRNAs target mRNA transcripts by binding complementarily to their 3' ends. Each individual miRNA can have hundreds of potential mRNA targets, and each target mRNA can be regulated by multiple miRNA making these two processes even more diverse. MiRNAs have many implications in neuronal and non-neuronal diseases, as discussed in the next section.

MicroRNA function and dysfunction

Regulation of miRNA abundance is important for regulating many biological functions such as cell differentiation, stem cell proliferation, and even specific regulations involved in aging (Kim, 2005a; Erson & Petty, 2008; Hackl et al., 2010). We find in many cases that the expressions of miRNAs are significantly different between normal and diseased tissue deeming miRNA expression a potential biomarker for many diseases. In patients with cancer, miRNAs function as tumor suppressors through regulation of apoptosis and oncogenes through inhibition of tumor suppressor genes (Erson & Petty, 2009). In 2002, the first miRNAs involved in cancer were

- Gerstel, B., Tuite, M. F., & McCarthy, J. E. (1992). The effects of 5'-capping, 3'-polyadenylation and leader composition upon the translation and stability of mRNA in a cell-free extract derived from the yeast *Saccharomyces cerevisiae*. *Molecular Microbiology*, 6(16), 2339-2348. doi: 10.1111/j.1365-2958.1992.tb01409
- Giraldez, A. J., Cinalli, R. M., Glasner, M. E., Enright, A. J., Thomas, J. M., Baskerville, S., . . . Schier, A. F. (2005). MicroRNAs regulate brain morphogenesis in zebrafish. *Science*, 308(5723), 833-838. doi: 10.1126/science.1109020
- Gregory, R. I., Yun, K. P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., & Slekhattar, R. (2004). The Microprocessor complex mediates the genesis of microRNAs. *Letters to Nature*, 432(7014), 235-240. doi: 10.1038/nature03120
- Hackl, M., Brunner, S., Fortschegger, K., Schreiner C., Micutkova, L., Muck, C., . . . Grillari, J. (2010). miR-17, miR-19b, miR-20a, miR-106a are down-regulated in human aging. *Aging Cell*, 9(2), 291-296. doi: 10.1111/j.1474-9726.2010.00549
- Han, J., Lee, Y., Yeom, K. H., Kim, Y. K., Jin, J., & Kim, V. N. (2004). The Drosha-DGCR8 complex in primary microRNA processing. *Genes and Development*, 18(24), 3016-3027. doi: 10.1101/gad.1262504
- Han, J., Lee, Y., Yeom, K. H., Nam, J. W., Heo, I., Rhee, J. K., . . . Kim, V. N. (2006). Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. *Cell*, 125(5), 887-901. doi: 10.1016/j.cell.2006.03.043
- Havens, M.A., Reich, A.A., Duelli, D.M., & Hastings, M.L. (2012). Biogenesis of mammalian microRNAs by a non-canonical processing pathway. *Nucleic Acids Research*, 40(10), 4626-4620. doi: 10.1093/nar/gks026
- Heo, I., Joo, C., Cho., J., Ha, M., Han, J., & Kim, V. N. (2008). Lin28 Mediates the Terminal Uridylation of let-7 Precursor MicroRNA. *Cell*, 32(2), 276-284. doi: 10.1016/j.molcel.2008.09.014
- Heneghan, H. M., Miller, N., McAnena, O. J., O'Brien, T., & Kerin, M. J. (2011). Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. *Journal of Clinical Endocrinology and Metabolism*, 96(5), E846-E850. doi: 10.1210/jc.2010-2701
- Hoffman, J. D., Hallam, S. E., Venne, V. L., Lyon, E., & Ward, K. (1998). Implications of a novel splice site in the BRCA1 gene. *American Journal of Medical Genetics*, 80(2), 140-144. doi: 10.1002/(SICI)1096-8628(19981102)80:2<140::AID-AJMG10>3.0.CO;2-L
- Hollander, J. A., Im, H. I., Amelio, A. L., Kocerha, J., Bali, P., Lu, Q., . . . Kenny, P. J. (2010). Striatal microRNA controls cocaine intake through CREB signaling. *Nature*, 466(7303), 197-202. doi: 10.1038/nature09202
- Human Genome Program. (2013). History of the Human

- Genome Project. Human Genome Project Information. Retrieved from website of the Office of Biological and Environmental Research of the U.S. Department of Energy Office of Science http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml
- Ibrahim, A. F., Weirauch, U., Thomas, M., Grunweller, A., Hartmann, R. K., & Aigner, A. (2011). MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. *Cancer Research*, 71(15), 5214-5224. doi: 10.1158/0008-5472.CAN-10-4645
- Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S., . . . Croce, C. M. (2005). MicroRNA gene expression deregulation in human breast cancer. *Cancer Research*, 65, 7065-7070. doi: 10.1158/0008-5472.CAN-05-1783
- Jafarnejad, S. M., Sjoestroem, C., Martinka, M., & Li, G. (2013). Expression of the RNase II enzyme Drosha is reduced during progression of human cutaneous melanoma. *Modern Pathology*, 1-9. doi:10.1038/modpathol.2012.225
- Jin, P., Zarnescu, D. C., Ceman, S., Nakamoto, M., Mowrey, J., Jongens, T. A., . . . Warren, S. T. (2004). Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. *Nature*, 7(2), 113-117. doi:10.1038/nn1174
- Jodelka, F.M., Ebert, A. D., Duelli, D. M., & Hastings, M. L. (2010). A feedback loop regulates splicing of the spinal muscular atrophy-modifying gene, SMN2. *Human Molecular Genetics*, 19(24), 4906-4917. doi: 10.1093/hmg/ddq425
- Keleman, O., Convertini, P., Zhang, Z., Wen, Y., Shen, M., Falaleeva, M., & Stamm, S. (2012). Function of alternative splicing. *Gene*, 514(1), 1-30. doi: 10.1016/j.gene.2012.07.083
- Ketting, R. F., Fischer, S. E., Bernstein, E., Sijen, T., Hannon, G. J., & Plasterk, R. H. (2001). Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in *Caenorhabditis elegans*. *Science*, 15(20), 2269-2271. doi: 10.1101/gad.927801
- Kim, J., Inoue, K., Ishii, J., Vanti, W. B., Voronov, S. V., Murchison, E., . . . Abeliovich, A. (2007). A microRNA feedback circuit in midbrain dopamine neurons. *Science*, 317(5842), 1220-1224. doi: 10.1126/science.1140481
- Kim, Y. K., & Kim, V. N. (2007). Processing of intronic microRNAs. *The EMBO Journal*, 26(3), 775-783. doi: 10.1038/sj.emboj.7601512
- Kim, V. N. (2005a). MicroRNA biogenesis: coordinated cropping and dicing. *Nature Reviews*, 6(5), 376-385. doi:10.1038/nrm1644
- Kim, V. N., Han, J., & Siomi, M.C. (2009). Biogenesis of small RNAs in animals. *Nature Reviews*, 10(2), 126-139. doi: 10.1038/nrm2632

- Kim, V. N. (2005b). Small RNAs: classification, biogenesis, and function. *Molecules and Cells*, 19(1), 1-15. <http://www.ncbi.nlm.nih.gov/pubmed/15750334>
- Klamt, B., Koziell, A., Poulat, F., Wieackker, P., Scambler, P., Berta, P., & Gessler, M. (1998). Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms. *Human Molecular Genetics*, 7(4), 709-714. doi: 10.1093/hmg/7.4.709
- Kozomara, A., & Griffiths-Jones, S. (2010). MiRBase: integrating microRNA annotation and deep-sequencing data. *Nucleic Acids Research*, 39, D152-D157. doi: 10.1093/nar/gkq1027
- Krichevsky, A. M., King, K. S., Donahue, C. P., Khrapko, K., Koski, K. S. (2003). A microRNA array reveals extensive regulation of microRNAs during brain development. *RNA*, 9(10), 1274-1281. doi:10.1261/rna.5980303
- Kuss, A. W., & Chen, W. (2008). MicroRNAs in brain function and disease. *Current Neurology and Neuroscience Reports*, 8(3), 190-197. <http://www.ncbi.nlm.nih.gov/pubmed/18541114>
- Lai, E. C. (2003). MicroRNAs: Runts of the genome assert themselves. *Current Biology*, 13(23), R925-R936. doi: 10.1016/j.cub.2003.11.017
- Lee, S. O., Masyuk, T., Splinter, P., Banales, J. M., Masyuk, A., Stroope, A., & Larusso, N. (2008). MicroRNA15a modulates expression of the cell-cell regulator Cdc25A and affects hepatic cystogenesis in rat model of polycystic kidney disease. *Journal of Clinical Investigation*, 118(11), 3714-3724. doi: 10.1172/JCI34922
- Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell*, 75(5), 843-854. doi: 10.1016/0092-8674(93)90529-Y
- Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., . . . Kim, V. N. (2003). The nuclear RNase II Drosha initiates microRNA processing. *Nature*, 425(6956), 415-419. doi:10.1038/nature01957
- Lee, Y., Kim, M., Han, J., Yeom, K., Lee, S., Baek, S. H., & Kim, V. N. (2004). MicroRNA genes are transcribed by RNA polymerase II. *The EMBO Journal*, 23(20), 4051-4060. doi: 10.1038/sj.emboj.7600385
- Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Bulet, P., Viollet, L., . . . Melki, J. (1995). Identification and characterization of a spinal muscular atrophy-determining gene. *Cell*, 80(1), 155-165. doi: 10.1016/0092-8674(95)90460-3
- Li, Q., Lee, J. A., & Black, D. L. (2007). Neuronal regulation of alternative pre-mRNA splicing. *Nature Reviews: Neuroscience*, 8, 819- 831. doi:10.1038/nrn2237

- Licatalosi, D. D., & Darnell, R. B. (2006). Splicing regulation in neurological disease. *Neuron*, 52(1), 93-101. doi: 10.1016/j.neuron.2006.09.017
- Liu, Q., Fischer, U., Wang, F., & Dreyfuss, G. (1997). The spinal muscular atrophy disease gene product, SMN, and its associated protein, SIP1, are in a complex with spliceosomal snRNP proteins. *Cell*, 90(6), 1013-1021. doi: 10.1016/S0092-8674(00)80367-0
- Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., . . . Golub, T. R. (2005). MicroRNA expression profiles classify human cancers. *Letters to Nature*. 435(7043), 834-838. doi:10.1038/nature03702
- Lund, E., Guttlinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004). Nuclear export of microRNA precursors. *Science*, 303(5654), 95-98. doi: 10.1126/science.1090599
- Macias, S., Plass, M., Stajuda, A., Michlewski, G., Eyras, E., & Caceres, J. F. (2012). DGCR8 HITS-CLIP reveals novel functions for the Microprocessor. *Nature Structural and Molecular Biology*, 19(8), 760-768. doi: 10.1038/nsmb.2344
- Maes, O. C., Chertkow, H. M., Wang, E., & Schipper, H. M. (2009). MicroRNA: implications for Alzheimer's disease and other human CNS. *Current Genomics*, 10(3), 154-168. doi: 10.2174/138920209788185252
- Michlewski, G., & Caceres, J. F. (2010). Antagonistic role of hnRNP A1 and KSRP in the regulation of *let-7a* biogenesis. *Nature Structural & Molecular Biology*, 17(8), 1011-1018. doi: 10.1038/nsmb.1874
- Miller, B. H., Zeier, Z., Xi, L., Lanz, T. A., Deng, S., Strathmann, J., . . . Wahlestedt, C. (2011). MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. *Proceedings of the National Academy of Sciences*, 109(8), 1-6. doi: 10.1073/pnas.1113793109
- Minones-Moyano, E., Porta, S., Escaramis, G., Rabionet, R., Iraola, S., Kagerbauer, B., . . . Marti, E. (2011). MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. *Human Molecular Genetics*, 20(15), 3067-3078. doi: 10.1093/hmg/ddr210
- Miranda, R. C., Pietrzykowski, A. Z., Tang, Y., Sathyan, P., Mayfield, D., . . . Hereld, D. (2010). MicroRNAs: master regulators of ethanol abuse and toxicity. *Alcoholism: Clinical and Experimental Research*, 34(4), 575-587. doi: 10.1111/j.1530-0277/2009.01126
- Morlando, M., Ballarino, M., Gromak, N., Pagano, F., Bozzoni, I., & Proudfoot, N. J. (2008). Primary microRNA transcripts are processed co-transcriptionally. *Nature Structural and Molecular Biology*, 15(9), 902-909. doi:10.1038/nsmb.1475
- Norris, A. D., & Calarco, J. A. (2012). Emerging roles of alternative pre-mRNA splicing regulation in neuronal

- development and function. *Frontiers in Neuroscience*, 6(122), 1-11. doi: 10.3389/fnins.2012.00122
- Pasquinelli, A. E., Reinhart, B. J., Slack, F., Martindale, M. Q., Kuroda, M. I., Maller, B., . . . Ruvkun, G. (2000). Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. *Nature*, 408(6808), 86-89. doi:10.1038/35040556
- Pan, Q., Shai, O., Lee, L. J., Frey, B. J., & Blencowe, B. J. (2008). Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. *Nature Genetics*, 40(12), 1413-1415. doi: 10.1038/ng.259
- Pietrzykowski, A. Z., Frieson, R. M., Martin, G. E., Puig, S. I., Nowak, C. L., Wynne, P. M., . . . Treisman, S. N. (2008). Post-transcriptional regulation of BK channel splice variant stability by miR-9 underlies neuroadaptation to alcohol. *Neuron*, 59(2), 274-287. doi: 10.1016/j.neuron.2008.05.032
- Reinhart, B. J., Slack, F. J., Basson, M., Pasquinelli, A. E., Bettinger, J. C., Rougvie, A. E., . . . Ruvkun, G. (2000). The 21-nucleotide let-7 RNA regulated developmental timing in *Caenorhabditis elegans*. *Nature*, 403(6772), 901-906. doi:10.1038/35002607
- Richter-Cook, N. J., Denver, T. E., Hensold, J. O., & Merrick, W. C. (1998). Purification and characterization of a new eukaryotic protein translation factor. *Journal of Biological Chemistry*, 273(13), 7579-7587. doi:10.1074/jbc.273.13.7579
- Richter, N. J., Rogers, G. W., Hensold, J. O., & Merrick, W. C. (1999). Further biochemical and kinetic characterization of human eukaryotic initiation factor 4H. *Journal of Biological Chemistry*, 274(50), 35415-35424. doi:10.1074/jbc.274.50.35415
- Roca, X. & Krainer, A. R. (2009) Recognition of atypical 5' splice sites by shifted base-pairing to U1 snRNA. *Nature Structural Molecular Biology*, 16(2), 176-182. doi: 10.1038/nsmb.1546
- Schaefer, A., O'Carroll, D., Tan, C. L., Hillman, D., Sugimori, M., Llinas, R., & Greengard, P. (2007). Cerebellar neurodegeneration in the absence of microRNAs. *The Journal of Experimental Medicine*, 204(7), 1553-1558. doi: 10.1084/jem.20070823
- Schratt, G. M., Tuebing, F., Nigh, E. A., Kane, C. G., Sabatini, M. E., Kiebler, M., & Greenberg, M. E. (2006). A brain-specific microRNA regulates dendritic spine development. *Nature*, 439(7074), 283-289. doi:10.1038/nature04367
- Sebastiani, G., Greico, F. A., Spagnuolo, F., Galleri, L., Cataldo, D., & Dotta, F. (2011). Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. *Metabolism Research and Reviews*, 27(8), 862-866. doi: 10.1002/dmrr.1262
- Shao, N. Y., Hu, H., Yan, Z., Xu, Y., Hu, H., Menzel, C., . . . Khaitovich, P. (2010). Comprehensive survey of human brain microRNA by deep sequencing. *BMC Genomics*, 11, 409. doi: 10.1186/1471-2164-11-409.
- Shiohama, A., Sasaki, T., Noda, S., Minoshima, S., & Shimizu, N. (2007). Nucleolar localization of DGCR8 and identification of eleven DGCR8-associated proteins. *Experimental Cell Research*, 313(20), 4196-4207. doi: 10.1016/j.yexcr.2007.07.020
- Shomron, N., & Levy, C. (2009). MicroRNA-biogenesis and pre-mRNA splicing crosstalk. *Journal of Biomedicine and Biotechnology*, 2009, 1-6. doi: 10.1155/2009/594678
- Stamm, S., Ben-Ari, S., Rafalska, I., Tang, Y., Zhang, Z., Toiber, D., . . . Soreq, H. (2005). Function of alternative splicing. *Gene*, 344, 1-20. doi: 10.1016/j.gene.2004.10.022
- Tazi, J., Bakkour, N., & Stamm, S. (2009). Alternative splicing and disease. *Biochimica et Biophysica Acta*, 1792(1), 14-26. doi: 10.1016/j.bbadis.2008.09.017
- Thum, T., Galuppo, P., Wolf, C., Fiedler, J., Kneitz, S., van Laake, L. W., . . . Bauersachs, J. (2007). MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. *Journal of the American Heart Association*, 116(3), 258-267. doi: 10.1161/CIRCULATIONAHA.107.687947
- Tomonaga, T., Matsushita, K., & Yamaguchi, S. (2011). Identification of altered protein expression and post-transcriptional modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. *Clinical Cancer Research*, 10(6), 2007-2014. doi: 10.1158/1078-0432.CCR-03-0321
- Ullrich, B., Ushkaryov, Y. A., & Sudhof, T. C. (1995). Cartography of neurexins: More than 1000 isoforms have been generated by alternative splicing and expressed in distinct subsets of neurons. *Neuron*, 14(3), 497-507. doi: 10.1016/0896-6273(95)90306-2
- Venables, J. P. (2004). Aberrant and alternative splicing in cancer. *Cancer Research*, 64(21), 7647-7654. doi: 10.1158/0008-5472.CAN-04-1910
- Wang, W. X., Rajeev, B. W., Stromberg, A. J., Ren, N., Tang, G., Huang, Q., . . . Nelson, P. T. (2008). The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of β -site amyloid precursor protein-cleaving enzyme 1. *The Journal of Neuroscience*, 28(5), 1213-1223. doi: 10.1523/JNEUROSCI.5065-07.2008
- Wang, Z., & Burge, C. B. (2008) Splicing regulation: From a parts list of regulatory elements to an integrated splicing code. *RNA*, 14(5), 802-813. doi: 10.1261/rna.876308
- Wang, E. T., Sandberg, R., Luo, S., Khrebtkova, I., Zhang, L., Mayr, C., . . . Burge, C. B. (2008). Alternative isoform regulation in human transcriptome. *Nature*, 456(7221), 470-476. doi:10.1038/nature07509

- West, A. E., & Greenberg, M. E. (2011). Neuronal activity-regulated gene transcription in synapse development and cognitive function. *Cold Spring Harbor Perspective Biology*, 3(6), 1-21. doi: 10.1101/cshperspect.a005744
- Wu, D., Matsushita, K., Matsubara, H., Nomura, F., & Tomonaga, T. (2011). An alternative splicing isoform of eukaryotic initiation factor 4H promotes tumorigenesis in vitro and is a potential therapeutic target for human cancer. *International Journal of Cancer*, 128(5), 1018-1030. doi: 10.1002/ijc.25419
- Yeo, G., Holste, D., Kreiman, G., & Burge, C. B. (2004). Variation in alternative splicing across human tissues. *Genome Biology*, 5(10), R74. doi: 10.1186/gb-2004-5-10-r74
- Yi, R., Qin, Y., Macara, I. G., & Cullen B. R. (2003). Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. *Genes and Development*, 17(24), 3011-3016. doi: 10.1101/gad.1158803
- Zhang, B., Pan, X., Cobb, G. P., & Anderson, T. A. (2007). MicroRNAs as oncogenes and tumor suppressors. *Developmental Biology*, 302(1), 1-12. doi: 10.1016/j.ydbio.2006.08.028

To view the full text, go to www.lakeforest.edu/eukaryon